advanc
surgic
techniqu
immunosuppress
regimen
pivot
factor
optim
outcom
transplant
introduct
cyclosporin
tacrolimu
decad
later
herald
era
modern
immunosuppress
transplant
advanc
quasiexperiment
procedur
establish
accept
modal
treatment
varieti
endorgan
diseas
tabl
depict
recent
data
graft
patient
surviv
releas
unit
network
organ
share
uno
best
result
livingrel
kidney
transplant
approxim
recipi
aliv
function
allograft
year
transplant
greatest
progress
may
liver
transplant
surviv
rate
use
cyclosporin
compar
current
surviv
rate
surviv
rate
lung
heartlung
intestin
transplant
recipi
lag
behind
group
procedur
introduc
experi
gain
slowli
limit
number
oper
perform
current
fewer
intestin
transplant
perform
annual
unit
state
howev
patient
surviv
rate
highvolum
experienc
center
current
approach
improv
graft
patient
surviv
parallel
declin
mortal
infect
fig
recent
data
organ
procur
transplant
network
show
infectionrel
mortal
within
past
decad
continu
declin
type
organ
transplant
see
fig
nevertheless
infect
still
account
death
kidney
heart
transplant
recipi
lung
transplant
recipi
tabl
liver
transplant
recipi
approxim
mortal
within
first
posttranspl
year
infect
associ
although
calcineurin
inhibitor
mainstay
immunosuppress
decad
longterm
outcom
remain
suboptim
larg
due
renal
dysfunct
metabol
complic
cumul
exposur
agent
exampl
chronic
renal
dysfunct
develop
organ
transplant
recipi
increas
risk
death
approxim
fourfold
concern
spawn
grow
interest
new
regimen
enhanc
immunolog
toler
eg
receptor
inhibitor
basiliximab
celldeplet
antibodi
alemtuzumab
thymoglobulin
celldeplet
agent
increas
risk
cytomegaloviru
cmv
infect
use
agent
antireject
induct
therapi
also
confer
higher
risk
fungal
infect
frequenc
type
infect
specif
pathogen
encount
transplant
gener
follow
predict
time
onset
thu
infect
transplant
recipi
must
evalu
context
time
sinc
transplant
evolv
medic
practic
prevent
strategi
modifi
risk
timelin
mani
infect
discuss
later
infect
period
primarili
surgic
technic
complic
relat
transplant
health
care
associ
bacteri
infect
includ
due
antimicrobialresist
pathogen
far
frequent
occur
infect
vascularcathet
infect
health
careassoci
pneumonia
clostridium
difficil
coliti
surgicalsit
infect
common
type
absenc
antifung
prophylaxi
candidiasi
aspergillosi
typic
occur
first
month
transplant
except
reactiv
herp
simplex
viru
hsv
viral
infect
commonli
encount
earli
transplant
certain
donortransmit
infect
discuss
later
may
also
manifest
period
although
nosocomi
infect
continu
pose
threat
patient
requir
prolong
hospit
surgic
infect
declin
import
month
typic
opportunist
infect
associ
immunosuppress
state
emerg
includ
pneumocysti
jirovecii
fungi
toxoplasma
gondii
nocardia
epidemiolog
infect
organ
transplant
recipi
typic
repres
opportunist
infect
reactiv
latent
organ
complic
relat
surgeri
health
careassoci
infect
infect
may
also
donor
deriv
advanc
medic
practic
prevent
strategi
modifi
risk
timelin
mani
infect
current
era
bacteri
infect
frequent
occur
infect
bacteremia
occur
transplant
recipi
fungal
infect
occur
patient
major
due
candida
aspergillu
spp
cryptococcu
endem
mycos
nonaspergillu
mold
account
other
cytomegaloviru
cmv
major
viral
infect
era
routin
antivir
prophylaxi
cmv
diseas
typic
occur
late
posttranspl
period
herp
virus
herp
simplex
viru
varicellazost
viru
epsteinbarr
viru
human
herpesviru
also
seen
greater
frequenc
sever
transplant
patient
influenza
respiratori
virus
major
caus
morbid
mortal
especi
lung
transplant
recipi
bk
viru
nephropathi
emerg
import
caus
allograft
dysfunct
loss
kidney
transplant
patient
gener
principl
serolog
assay
although
valuabl
assess
past
exposur
reliabl
diagnosi
acut
infect
quantit
molecular
assay
prove
valuabl
tool
diagnosi
guid
preemptiv
therapi
monitor
respons
treatment
sever
viral
pathogen
late
manifest
may
repres
reactiv
chronic
viral
infect
herp
zoster
may
occur
time
transplant
number
tumor
relat
viral
infect
may
also
occur
late
wart
verruca
vulgari
frequent
infect
also
lymphoma
lymphoprolif
syndrom
relat
epsteinbarr
viru
ebv
occur
year
final
although
risk
classic
opportunist
infect
declin
never
disappear
complet
infect
due
mycos
cryptococcosi
histoplasmosi
often
manifest
late
without
appar
incit
event
chang
immunosuppress
importantli
cmv
histor
cmv
infect
diseas
occur
week
transplant
howev
era
routin
use
antivir
prophylaxi
typic
given
month
transplant
cmv
diseas
occur
later
antivir
prophylaxi
discontinu
lateonset
cmv
diseas
pneumocysti
pneumonia
larg
extent
toxoplasmosi
seen
infrequ
today
effect
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
invas
aspergillosi
long
regard
earlyoccur
infect
howev
case
occur
month
transplant
notabl
lung
transplant
recipi
aspergillu
infect
occur
month
median
time
onset
transplant
day
one
report
month
anoth
widespread
use
moldact
antifung
prophylaxi
chronic
reject
treatment
like
account
trend
infect
month
transplant
mostli
commun
acquir
similar
seen
gener
popul
howev
contemporari
data
spanish
consortium
common
infect
heart
transplant
bacteri
pneumonia
urinari
infect
herp
viru
infect
invas
fungal
infect
pneumonia
heart
transplant
recipi
mostli
caus
common
pathogen
bacteria
tabl
although
incid
pneumonia
highest
first
month
transplant
bacteri
pneumonia
occur
sporad
late
posttransplant
period
patient
recov
immedi
effect
surgeri
survey
heart
transplant
infect
includ
bacteremia
patient
aris
urinari
tract
year
transplant
half
renal
recipi
diagnos
upper
lower
urinari
tract
infect
mani
infect
uncompl
cystiti
graft
pyelonephr
occur
renal
recipi
period
studi
pyelonephr
occur
first
month
associ
reduc
graft
surviv
later
infect
howev
larger
multivari
analysi
kidney
recipi
medicar
databas
show
urinari
tract
infect
month
associ
wors
longterm
graft
function
surviv
abnorm
ureter
reflux
strictur
ureteroves
junction
neurogen
bladder
sought
patient
recurr
infect
administr
extend
cours
antibiot
week
consider
secondari
antibiot
prophylaxi
reason
patient
sever
graft
pyelonephr
recurr
infect
asymptomat
bacteriuria
common
kidney
transplant
recipi
insuffici
data
routin
screen
treatment
set
clinician
also
alert
occurr
uncommon
urinari
pathogen
exampl
urinari
tract
tuberculosi
may
aris
focu
nativ
kidney
mycoplasma
homini
may
caus
breakdown
ureteroves
anastomosi
subsequ
graft
loss
histoplasmosi
may
involv
transplant
kidney
caus
renal
failur
adenoviru
may
caus
hemorrhag
cystiti
nephriti
bk
viru
import
caus
renal
allograft
infect
typic
associ
clinic
sign
symptom
histor
pneumonia
occur
kidney
transplant
recipi
common
infecti
caus
death
past
transplantationassoci
pneumonia
often
due
cmv
opportunist
infect
fungi
nocardia
pneumocysti
recent
opportunist
agent
come
better
control
convent
bacteri
pathogen
becom
rel
common
transplant
popul
wound
infect
infrequ
may
seriou
problem
particularli
involv
perinephr
space
bodi
mass
index
greater
equal
kgm
urinari
leak
reoper
transplant
incis
mycophenol
mofetil
use
diabet
risk
factor
infect
renal
transplant
recipi
continu
frequent
problem
infect
even
first
month
patient
transplant
lung
infect
multifactori
addit
mechan
factor
relat
decreas
mucociliari
clearanc
diminish
lymphat
drainag
ablat
cough
reflex
appear
play
import
poorli
understood
role
type
infect
seen
lung
transplant
recipi
similar
heartlung
recipi
although
overal
surviv
rate
better
heartlung
transplant
usual
reserv
patient
eisenmeng
syndrom
whose
cardiac
abnorm
surgic
repair
singleand
doublelung
procedur
leav
donor
heart
avail
anoth
patient
endstag
heart
diseas
uniqu
aspect
singlelung
transplant
occurr
infect
nativ
lung
may
predispos
infect
defect
ventil
perfus
caus
underli
lung
diseas
lung
heartlung
transplant
recipi
experi
high
rate
bacteri
lung
infect
especi
first
week
transplant
patient
also
higher
rate
mediastin
invas
fungal
infect
cmv
pneumonia
heart
recipi
patient
undergo
lung
transplant
chronic
colon
multidrugresist
bacteria
eg
cystic
fibrosi
noncyst
fibrosi
bronchiectasi
therefor
high
risk
postop
infect
time
transplant
surgeri
antimicrobi
treatment
direct
pretranspl
colon
bacteria
typic
given
sever
week
transplant
pretranspl
colon
certain
burkholderia
spp
burkholderia
cenocepacia
particular
associ
sever
infect
decreas
surviv
transplant
thu
mani
transplant
center
consid
pretranspl
b
cenocepacia
colon
infect
contraind
lung
transplant
heartlung
lung
transplant
recipi
develop
invas
pulmonari
aspergillosi
frequent
patient
type
organ
transplant
risk
factor
includ
pretranspl
colon
singl
lung
transplant
augment
immunosuppress
allograft
reject
uniqu
form
aspergillosi
involv
airway
mucosa
bronchial
anastomot
site
call
tracheobronchi
aspergillosi
observ
almost
exclus
lung
heartlung
recipi
airway
lesion
diseas
directli
visual
bronchoscopi
form
aspergillosi
better
prognosi
aspergillosi
invad
lung
parenchyma
predisposit
lung
recipi
invas
aspergillosi
led
mani
lung
transplant
center
routin
use
variou
target
antifung
prevent
strategi
oral
azol
inhal
amphotericin
wide
use
agent
late
posttranspl
period
two
third
patient
eventu
develop
oblit
bronchiol
process
main
patholog
manifest
chronic
reject
lung
associ
recurr
pulmonari
infect
one
major
caus
death
lung
transplant
patient
lung
allograft
also
particularli
suscept
viral
infect
document
cmv
hsv
paramyxovirus
adenoviru
infect
accordingli
lung
transplant
center
often
util
aggress
regimen
prevent
herpesviru
infect
includ
diagnost
test
respiratori
virus
workup
patient
present
acut
chest
infect
communityacquir
respiratori
viru
infect
influenza
parainfluenza
respiratori
syncyti
viru
rsv
metapneumoviru
coronaviru
rhinoviru
adenoviru
signific
caus
morbid
associ
shortterm
longterm
impair
allograft
infect
influenza
therapi
proven
improv
outcom
respiratori
virus
pulmonari
nontubercul
mycobacteri
infect
rel
common
lung
transplant
recipi
may
aris
pretranspl
colon
strain
exogen
acquisit
mycobacterium
abscessu
associ
sever
infect
transplant
center
exclud
patient
pretranspl
abscessu
infect
colon
diseas
pretranspl
colon
nontubercul
mycobacteria
appear
close
associ
decreas
surviv
sever
posttranspl
infect
prospect
donor
lung
transplant
intub
intens
care
unit
therefor
airway
donor
often
colon
microorgan
occult
parenchym
infect
may
present
implant
lung
customari
obtain
recipi
stanford
univers
infect
common
caus
death
mediastin
sternal
wound
infect
postop
complic
uniqu
heart
heartlung
transplant
recipi
occur
approxim
patient
pathogen
seen
similar
observ
patient
undergo
cardiothorac
surgeri
staphylococci
predomin
one
must
also
alert
possibl
unusu
pathogen
mediastin
sternal
wound
infect
heart
recipi
caus
homini
legionella
aspergillu
mucormycet
nocardia
factor
thought
predispos
mediastin
popul
repeat
oper
hemorrhag
use
antireject
therapi
diabet
mellitu
surgic
drainag
crucial
compon
treatment
mediastin
transplant
patient
leftventricular
assist
devic
lvad
wide
use
bridg
transplant
infect
devic
common
fall
distinct
type
drivelin
infect
often
limit
exit
site
deep
infect
pocket
surround
devic
intern
infect
devic
often
associ
bloodstream
infect
manag
infect
challeng
howev
mani
case
infect
control
well
enough
permit
transplant
avail
experi
suggest
use
antimicrobi
therapi
transplant
associ
fewer
relaps
shortcours
therapi
although
pretranspl
lvad
infect
associ
higher
rate
periheart
transplant
complic
longterm
outcom
appear
reason
lvad
infect
consid
contraind
heart
transplant
number
infect
occur
commonli
heart
recipi
patient
receiv
type
transplant
includ
toxoplasmosi
nocardiosi
chaga
diseas
toxoplasmaseroneg
heart
recipi
risk
toxoplasmosi
infect
acquir
organ
encyst
heart
muscl
toxoplasmaseroposit
donor
clinic
toxoplasmosi
usual
occur
week
month
transplant
manifest
necrot
pneumon
myocard
enceph
use
prevent
therapi
rate
toxoplasmosi
donor
toxoplasma
seropositiverecipi
seroneg
patient
approxim
toxoplasma
seroposit
recipi
clinic
toxoplasmosi
uncommon
heart
recipi
like
use
tmpsmx
pneumocysti
prophylaxi
symptomat
reactiv
trypanosoma
cruzi
may
seen
immunocompromis
patient
includ
transplant
recipi
one
fourth
patient
undergo
heart
transplant
cardiomyopathi
caus
chronic
cruzi
infect
relaps
acut
chaga
diseas
clinic
manifest
fever
myocard
skin
lesion
diseas
usual
control
chemotherapi
detect
parasitemia
microscopi
polymeras
chain
reaction
pcr
blood
sampl
use
monitor
reactiv
guid
chemotherapi
transplant
nocardia
infect
also
frequent
report
heart
lung
transplant
recipi
recipi
kidney
liver
transplant
biolog
reason
increas
rate
nocardiosi
unknown
dose
tmpsmx
use
pneumocysti
prophylaxi
might
provid
reliabl
protect
nocardia
infect
heart
recipi
frequent
suffer
trauma
tricuspid
valv
right
ventricular
endocardium
repeat
endomyocardi
biopsi
common
posttransplant
practic
heart
transplant
patient
cardiac
valvulopathi
high
risk
advers
outcom
endocard
prophylaxi
dental
procedur
consid
appropri
group
case
occur
first
year
transplant
may
caus
unusu
organ
aspergillu
legionella
speci
lung
heartlung
transplant
recipi
infecti
problem
larg
similar
heart
transplant
recipi
infect
frequent
sever
heighten
vulner
diagnosi
cholang
mani
patient
manifest
classic
charcot
triad
fever
abdomin
pain
jaundic
clinic
present
may
resembl
allograft
reject
diagnosi
reliabl
bacteremia
present
liver
biopsi
indic
pericholang
empir
treatment
cholang
includ
antibiot
cover
gramneg
enter
bacilli
enterococci
anaerob
procedur
ttube
cholangiographi
endoscop
retrograd
cholangiopancreatographi
may
follow
cholang
occasion
bacteremia
therefor
singl
dose
prophylact
antibiot
recommend
periton
accompani
intraabdomin
infect
frequent
complic
biliari
leak
disrupt
abdomin
viscu
bile
periton
may
occur
extract
ttube
often
well
toler
may
resolv
occasion
leak
persist
chemic
periton
becom
secondarili
infect
common
organ
involv
periton
enterococci
aerob
enter
gramneg
rod
staphylococc
candid
infect
infrequ
treatment
establish
periton
requir
antibiot
therapi
togeth
drainag
associ
abscess
repair
technic
problem
biliari
leak
abdomin
abscess
usual
found
patient
frequent
lengthi
abdomin
oper
nearli
one
third
abdomin
abscess
associ
bacteremia
locat
frequent
subhepat
splenic
pericol
pelvic
abscess
also
seen
patient
abscess
undergon
abdomin
oper
within
preced
day
although
common
enter
organ
caus
abscess
staphylococci
candida
also
seen
imag
studi
usual
defin
locat
abscess
abscess
appropri
treatment
combin
drainag
antibiot
direct
respons
pathogen
pancrea
transplant
oper
perform
unit
state
annual
approxim
everi
renal
transplant
current
patient
graft
surviv
rate
similar
kidney
transplant
alon
infectionrel
morbid
higher
studi
shown
wound
complic
cmv
diseas
among
patient
receiv
combin
kidneypancrea
kidney
transplant
alon
postop
infect
rate
caus
pathogen
depend
primarili
techniqu
use
drainag
exocrin
secret
pancrea
recent
year
practic
drain
secret
small
bowel
enter
drainag
gain
preced
previou
practic
drainag
bladder
enter
drainag
associ
lower
rate
urinari
tract
infect
howev
intraabdomin
infect
remain
signific
complic
enter
drainag
procedur
aerob
anaerob
enter
bacteria
predomin
abscess
associ
enter
drainag
microorgan
infect
viscu
open
usual
skin
flora
candida
howev
common
pathogen
type
surgic
site
infect
includ
use
bladder
drainag
small
bowel
transplant
prefer
therapi
intestin
failur
total
parenter
nutritionrel
complic
small
bowel
transplant
uniqu
gut
harbor
larg
burden
lymphoid
tissu
also
cell
least
well
toler
organ
consequ
small
bowel
transplant
recipi
particularli
suscept
graftversushost
diseas
manag
risk
reject
infect
graftversushost
diseas
proven
challeng
small
bowel
transplant
often
combin
liver
graft
due
concurr
exist
intestin
failureassoci
liver
diseas
notabl
inclus
liver
graft
intestin
graft
may
immunolog
protect
howev
isol
intestin
transplant
becom
increasingli
frequent
like
due
improv
manag
intestin
failureassoci
liver
dysfunct
small
bowel
transplant
recipi
develop
signific
infect
rate
infect
higher
transplant
group
intraabdomin
pyogen
infect
bloodstream
infect
predomin
transplant
intestin
cultur
gram
stain
donor
airway
guid
antibiot
therapi
recipi
initi
antibiot
prophylaxi
aim
common
nosocomi
pathogen
encount
intens
care
unit
includ
methicillinresist
staphylococcu
aureu
enter
gramneg
bacilli
anoth
problem
uniqu
lung
transplant
dehisc
airway
anastomosi
occur
first
week
transplant
frequent
associ
bacteri
fungal
infect
anastomot
site
incid
complic
appear
declin
liver
transplant
recipi
higher
rate
infect
renal
heart
transplant
recipi
death
associ
infect
either
primari
secondari
caus
see
tabl
bacteri
infect
occur
patient
liver
transplant
half
infect
occur
within
week
transplant
import
site
infect
abdomen
biliari
tract
surgic
wound
lung
bloodstream
without
associ
cathet
infect
liver
transplant
recipi
high
rate
fungal
infect
incid
rang
casefat
rate
risk
factor
invas
fungal
infect
includ
renal
dysfunct
fulmin
hepat
failur
longer
oper
time
retransplant
hepat
iron
overload
colon
candida
time
transplant
candida
predomin
pathogen
caus
invas
fungal
infect
popul
although
declin
rel
import
compar
aspergillu
mold
cryptococcu
almost
one
third
candid
infect
liver
transplant
recipi
caus
nonalbican
speci
fluconazol
prophylaxi
found
risk
factor
emerg
nonalbican
candida
speci
pathogen
liver
transplant
recipi
invas
candidiasi
contribut
significantli
mortal
liver
transplant
casecontrol
studi
liver
transplant
recipi
invas
candidiasi
mortal
rate
compar
control
patient
invas
aspergillosi
occur
liver
transplant
recipi
major
risk
factor
invas
aspergillosi
liver
transplant
includ
retransplant
fulmin
hepat
failur
indic
transplant
renal
dysfunct
hemodialysi
poor
allograft
function
aspergillu
infect
occur
day
transplant
possibl
consequ
improv
earli
manag
delay
occurr
risk
factor
cmv
infect
liver
transplant
recipi
uniqu
predispos
dissemin
aspergillosi
transplant
liver
differ
transplant
oper
length
difficulti
surgeri
frequenc
bleed
addit
mani
liver
transplant
recipi
poor
nutrit
sever
metabol
difficulti
abdomin
infect
liver
transplant
often
relat
technic
aspect
complic
oper
exampl
anastomosi
biliari
duct
rouxeni
loop
jejunum
associ
intraabdomin
infect
especi
invas
fungal
infect
primari
anastomosi
donor
recipi
common
bile
duct
liver
abscess
transplant
liver
relat
surgic
problem
biliari
strictur
hepat
arteri
thrombosi
organ
respons
gramneg
enter
bacilli
enterococci
anaerob
diagnosi
made
ultrasonographi
comput
tomographi
treatment
drainag
intraven
antibiot
usual
success
provid
sourc
biliari
infect
structur
abnorm
correct
hepat
arteri
thrombosi
predispos
factor
infecti
symptom
usual
control
antibiot
retransplant
may
necessari
cholang
liver
transplant
also
result
technic
problem
common
predispos
problem
biliari
strictur
patient
strictur
may
period
bout
cholang
patient
improv
dilat
procedur
stent
placement
other
oper
repair
necessari
may
easi
make
firm
abdomen
includ
biliari
tract
intraven
cathet
soft
tissu
inabl
discern
sourc
rare
especi
liver
transplant
recipi
bacteremia
liver
transplant
recipi
document
sourc
probabl
origin
abdomen
trend
increas
antimicrobi
resist
among
gramneg
bloodstream
isol
may
affect
local
decis
regard
empir
antibiot
therapi
transplant
patient
present
possibl
bloodstream
infect
usual
microbi
caus
pneumonia
transplant
recipi
list
tabl
subdivid
accord
whether
pneumonia
occur
first
month
transplant
later
whether
caus
common
less
common
key
manag
pulmonari
infect
transplant
recipi
rapid
identif
respons
pathogen
initi
specif
therapi
patient
brief
durat
symptom
day
focal
chest
infiltr
produc
sputum
neutrophil
gram
stain
like
routin
bacteri
pneumonia
empir
therapi
cover
common
typic
atyp
bacteri
pathogen
initi
cultur
result
await
patient
ill
last
longer
day
nonproduct
cough
diffus
infiltr
nodular
lesion
chest
imag
like
unusu
opportunist
pathogen
consider
given
time
use
invas
diagnost
procedur
includ
bronchoscopi
establish
diagnosi
nodular
infiltr
broad
rang
infecti
etiolog
tabl
certain
clinic
radiograph
featur
may
help
discern
specif
etiolog
invas
workup
also
indic
patient
deterior
rapidli
appear
convent
pneumonia
respond
treatment
frequenc
legionella
infect
vari
wide
depend
endem
hospit
sensit
diagnost
method
radiograph
present
variabl
may
includ
focal
infiltr
nodular
pleuralbas
lesion
lung
abscess
pleural
pericardi
effus
legionellosi
transplant
patient
treat
quinolon
antibiot
azithromycin
infect
caus
aspergillu
nocardia
endem
mycos
may
rel
common
region
communityacquir
respiratori
virus
like
lung
allograft
suscept
cmv
infect
includ
tendenc
relaps
success
antivir
treatment
multiviscer
transplant
recipi
patient
undergo
colon
segment
transplant
small
bowel
transplant
like
develop
infect
suscept
small
bowel
transplant
recipi
infect
continu
late
posttransplant
period
ie
month
oper
incid
ebvassoci
lymphoprolif
disord
approach
year
tumor
often
involv
gut
infect
skin
common
transplant
rare
lifethreaten
organ
transplant
recipi
risk
wound
infect
common
bacteri
pathogen
aureu
infect
enterococci
gramneg
bacteria
candida
homini
may
also
seen
rare
mucormycosi
caus
surgic
site
infect
transplant
recipi
subcutan
infect
caus
alternaria
exophiala
darkli
pigment
dematiac
fungi
encount
occasion
biopsi
fungal
cultur
requir
specif
diagnosi
cellul
necrot
infect
also
due
cryptococcosi
unlik
stem
cell
transplant
recipi
organ
transplant
recipi
rare
develop
fusariosi
common
cutan
viral
infect
caus
hsv
varicellazost
viru
vzv
wart
common
problem
particularli
year
transplant
skin
also
target
organ
mani
system
infect
bacteri
fungal
nocardi
mycobacteri
cmv
infect
may
includ
skin
manifest
mycobacterium
chelona
caus
nodular
lesion
often
extrem
rule
one
aggress
investig
new
unusu
skin
lesion
biopsi
urinari
tract
infect
discuss
earlier
see
kidney
transplant
recipi
bacteremia
occur
kidney
heart
transplant
recipi
higher
rate
liver
lung
transplant
recipi
see
tabl
besid
catheterrel
infect
pneumonia
heart
heartlung
transplant
recipi
urinari
tract
infect
perinephr
sourc
renal
transplant
recipi
abdomin
biliari
infect
liver
transplant
recipi
surgic
site
urinari
tract
infect
pancreat
transplant
recipi
commonli
identifi
sourc
bacteremia
predomin
gramneg
bacteria
escherischia
coli
klebsiella
spp
enterobacteriacea
includ
extendedspectrum
produc
organ
acinetobact
baumannii
pseudomona
aeruginosa
highest
incid
gramneg
bloodstream
infect
observ
within
first
month
transplant
personyear
sharp
declin
personyear
month
transplant
kidney
recipi
like
develop
gramneg
bacteremia
month
transplant
bacteremia
due
aureu
occur
estim
rate
variou
organ
transplant
recipi
rate
methicillinresist
aureu
increas
time
among
organ
transplant
recipi
lung
recipi
highest
incid
attack
rate
common
sourc
vascular
cathet
pneumonia
wound
infect
nearli
one
half
aureu
bacteremia
occur
within
day
transplant
earlyonset
bacteremia
like
occur
liver
transplant
probabl
due
larg
size
incis
colon
candidaci
unadjust
allcaus
mortal
gramneg
bloodstream
infect
transplant
recipi
kidney
recipi
lower
mortal
liver
transplant
recipi
basic
approach
bacteremia
whether
patient
undergon
transplant
includ
ascertain
sourc
bacteremia
like
pathogen
common
site
produc
bacteri
bloodstream
infect
lung
urinari
tract
iuml
transplant
reduc
rate
posttranspl
recurr
interferon
therapi
recommend
patient
decompens
cirrhosi
may
worsen
liver
diseas
poorli
toler
presenc
chronic
hbv
infect
also
advers
influenc
longterm
outcom
kidney
transplant
due
part
higher
rate
death
underli
cirrhosi
hepatocellular
carcinoma
hbvinfect
patient
find
underscor
import
care
evalu
hepat
serolog
liver
function
patient
present
candid
transplant
organ
liver
hbv
uninfect
liver
nonhepat
transplant
candid
receiv
hbv
vaccin
pretranspl
earli
possibl
cours
ill
although
respons
vaccin
might
suboptim
due
underli
diseas
hcv
infect
occur
transplant
group
preval
highest
among
liver
kidney
transplant
recipi
small
number
hcvinfect
transplant
recipi
organ
type
develop
progress
fatal
cholestat
liver
diseas
first
year
transplant
case
mark
high
viral
load
liver
biopsi
show
sever
hepatocyt
dropout
minim
parenchym
inflamm
longterm
outcom
hcvinfect
patient
depend
extent
organ
transplant
liver
transplant
candid
hcv
viremia
transplant
almost
alway
reinfect
liver
graft
transplant
develop
hepat
first
year
transplant
ongo
hcv
infect
lead
graft
cirrhosi
patient
year
transplant
find
nation
institut
diabet
digest
kidney
diseas
niddk
liver
transplant
databas
shown
longterm
outcom
year
liver
transplant
hcv
similar
liver
transplant
indic
howev
retrospect
analysi
liver
recipi
uno
databas
show
mediumterm
surviv
hcvinfect
patient
inferior
uninfect
patient
longitudin
studi
kidney
transplant
popul
also
shown
chronic
hcv
infect
advers
impact
surviv
effect
clearli
discern
second
decad
transplant
excess
death
due
direct
effect
liver
diseas
also
higher
rate
sepsi
sever
factor
shown
predict
progress
liver
diseas
due
hcv
transplant
liver
transplant
recipi
includ
degre
immunosuppress
use
antireject
therapi
high
viral
load
earli
transplant
older
donor
age
cmv
infect
studi
infect
hcv
type
although
choic
calcineurin
inhibitor
use
mycophenol
mofetil
conclus
shown
effect
hcv
recurr
rate
higher
cumul
exposur
corticosteroid
associ
increas
mortal
sever
histolog
recurr
hcv
antivir
treatment
recurr
hcv
infect
liver
transplant
activ
investig
interferon
monotherapi
produc
endoftreat
respons
liver
recipi
hcv
infect
patient
sustain
respons
month
later
use
combin
therapi
longact
pegyl
interferon
ribavirin
led
sustain
virolog
respons
rate
base
data
pegyl
interferon
without
ribavirin
treatment
choic
histopatholog
document
hepat
c
recurr
differ
opinion
optim
time
select
patient
treatment
actual
practic
interferon
ribavirin
side
effect
make
difficult
administ
liver
transplant
recipi
small
proport
patient
actual
abl
benefit
use
current
treatment
gener
use
patient
histolog
signific
diseas
grade
inflamm
grade
fibrosi
rather
preemptiv
infect
patient
develop
sever
new
class
directact
antivir
proteas
inhibitor
rna
polymeras
inhibitor
inhibitor
hosttarget
agent
cyclophilin
inhibitor
inhibit
hcv
replic
indic
initi
therapi
like
broaden
efficaci
newer
regimen
anticip
substanti
improv
compar
current
pegyl
interferonribavirin
regimen
influenza
parainfluenza
rsv
metapneumoviru
coronaviru
rhinoviru
adenoviru
may
caus
pneumonia
transplant
recipi
mycobacterium
tuberculosi
major
pulmonari
pathogen
particularli
geograph
area
tuberculosi
endem
intraabdomin
infect
liver
transplant
recipi
alreadi
discuss
infect
also
occur
increas
frequenc
among
recipi
pancrea
small
bowel
transplant
less
common
transplant
oper
involv
abdomen
occur
usual
relat
preexist
medic
condit
biliari
stone
diverticulosi
studi
develop
countri
show
transplant
recipi
suscept
salmonella
infect
infect
caus
shigella
campylobact
appear
increas
frequenc
c
difficil
coliti
emerg
one
common
caus
diarrhea
transplant
recipi
heavili
treat
antibiot
c
difficil
coliti
develop
transplant
recipi
case
occur
within
first
day
toxic
megacolon
may
develop
recurr
coliti
approxim
organ
transplant
recipi
c
difficil
coliti
helicobact
infect
associ
lowgrad
gastric
lymphoma
call
maltoma
small
number
transplant
recipi
tumor
regress
reduct
immunosuppress
use
antibiot
treat
helicobact
infect
hyperinfect
dissemin
infect
strongyloid
substanti
problem
past
appear
uncommon
univers
pretransplant
screen
strongyloid
probabl
costeffect
vigil
infect
maintain
patient
endem
area
import
caus
hepat
transplant
recipi
hepat
b
viru
hbv
hcv
cmv
less
frequent
hepat
patient
may
caus
hsv
vzv
adenoviru
human
herpesviru
liver
transplant
candid
chronic
hbv
infect
routin
reinfect
allograft
surviv
rate
transplant
patient
approxim
reinfect
rate
transplant
lower
outcom
better
patient
fulmin
hepat
b
infect
hepat
coinfect
repres
minor
patient
hbv
infect
uniqu
particularli
aggress
syndrom
recurr
hbv
infect
patient
hbv
recurr
fibros
cholestat
hepat
character
mark
cholestasi
hypoprothrombinemia
modest
increas
serum
transaminas
fibros
cholestat
hepat
like
occur
patient
pretranspl
hbv
replic
result
rapid
death
almost
case
pauciti
inflammatori
respons
syndrom
suggest
viru
may
directli
cytopath
past
mani
transplant
center
consid
chronic
hepat
b
infect
contraind
liver
transplant
current
era
outcom
patient
risk
recurr
hbv
infect
liver
transplant
greatli
improv
avail
agent
abl
prevent
treat
recurr
develop
quantit
molecular
assay
measur
hepat
b
viral
load
blood
effect
approach
prevent
recurr
hbv
use
posttranspl
combin
therapi
antivir
agent
hbig
addit
pretranspl
antivir
therapi
monotherapi
lamivudin
recommend
reappear
hbsag
liver
transplant
patient
newer
antivir
agent
includ
adefovir
dipivoxil
tenofovir
entecavir
also
avail
lamivudineresist
hbv
regardless
agent
use
hbv
viral
load
monitor
transplant
detect
breakthrough
infect
clinic
consequ
develop
antivir
therapi
hbv
modifi
persist
elev
viral
load
log
copiesml
transplant
candid
chronic
hbv
inact
hbsag
carrier
state
initi
antivir
therapi
hbv
continu
transplant
reduct
hbv
dna
undetect
level
minimum
less
cladophialophora
overal
mortal
rate
high
patient
cn
infect
caus
mucoral
dematiac
fungi
therapi
combin
antifung
medic
surgic
resect
gener
recommend
cryptococc
mening
usual
occur
late
posttransplant
period
subacut
cours
pulmonari
diseas
caus
cryptococcu
coexist
fungemia
present
case
lumbar
punctur
perform
patient
cryptococcosi
even
absenc
cn
sign
spinal
fluid
usual
fewer
white
blood
cellsml
lymphocyt
predomin
posit
cryptococc
antigen
test
india
ink
prepar
reveal
posit
find
patient
serum
cryptococc
antigen
posit
transplant
recipi
cn
cryptococcosi
patient
cn
cryptococcosi
cn
lesion
due
cryptococcu
neuroimag
new
lesion
develop
initi
antifung
therapi
may
repres
immun
reconstitut
syndrom
inflammatori
tissu
respons
result
improv
cellular
immun
reduct
cessat
immunosuppress
revers
cryptococcusassoci
immunosuppress
overal
mortal
solidorgan
transplant
recipi
cryptococcosi
approxim
receipt
calcineurin
inhibitor
associ
lower
mortal
rate
may
attribut
part
synergist
interact
calcineurin
inhibitor
antifung
azol
gondii
protozoan
caus
nonspecif
encephalopathi
diffus
meningoenceph
progress
singl
multipl
brain
lesion
toxoplasma
infect
report
type
solidorgan
transplant
often
describ
cardiac
transplant
organ
becom
encyst
cardiac
muscl
primari
infect
recipi
seroneg
statu
primari
infect
transplant
appear
like
mechan
donor
heart
becom
sourc
infect
nonimmun
cardiac
recipi
serolog
perform
cardiac
donor
recipi
identifi
patient
risk
diseas
transmit
allograft
fatal
rate
high
often
diagnosi
establish
autopsi
treatment
choic
pyrimethamin
mgday
sulfadiazin
gday
folin
acid
mgday
usual
ad
regimen
prevent
marrow
suppress
nocardiosi
may
caus
singl
multipl
brain
abscess
less
commonli
mening
primari
portal
infect
pulmonari
metastat
spread
bone
skin
cn
nocardia
brain
abscess
may
benefit
stereotact
biopsi
surgic
drainag
addit
longterm
antimicrobi
therapi
sulfonamid
mainstay
treatment
penetr
cn
well
isol
suscept
combin
therapi
typic
use
dissemin
diseas
agent
amikacin
imipenem
cefotaxim
shown
good
activ
rapid
kill
sulfonamid
jc
virusassoci
progress
multifoc
leukoencephalopathi
west
nile
viru
import
caus
cn
infect
discuss
separ
follow
section
cover
issu
relat
viral
infect
transplant
recipi
hepat
virus
discuss
earlier
approach
antivir
prophylaxi
pretransplant
evalu
candid
donor
discuss
elsewher
book
see
chapter
human
herpesviru
infect
transplant
recipi
consid
due
endogen
reactiv
latent
viru
rare
primari
infect
may
transmit
donor
overal
transplant
recipi
particularli
receiv
antivir
prophylaxi
cmv
may
develop
infect
typic
earli
posttranspl
period
patient
infect
asymptomat
may
manifest
febril
syndrom
leucopenia
rare
meningoenceph
howev
import
drug
interact
current
immunosuppress
major
challeng
use
agent
transplant
patient
earli
promis
result
newer
antivir
therapi
like
revolution
substanti
alter
treatment
hcv
infect
orthotop
liver
transplant
candid
recipi
hepat
e
viru
hev
compos
multipl
genotyp
endem
mani
region
world
viru
small
nonenvelop
rna
viru
transmit
fecalor
rout
previous
thought
caus
acut
hepat
howev
progress
chronic
hepat
may
occur
organ
transplant
recipi
avail
evid
suggest
import
mechan
primari
acquisit
transplant
rather
donortransmit
infect
reactiv
prior
pretranspl
infect
current
proven
effect
prevent
therapeut
option
hev
infect
although
small
seri
report
benefit
ribavirin
without
interferon
central
nervou
system
cn
infect
transplant
patient
requir
prompt
diagnosi
earli
appropri
therapi
tabl
list
import
agent
absent
notabl
list
pyogen
bacteria
hsv
otherwis
common
pathogen
transplant
patient
site
outsid
cn
highest
risk
opportunist
cn
infect
month
transplant
except
cryptococc
mening
often
late
event
listeria
monocytogen
typic
caus
bacteremia
mening
time
cerebr
transplant
recipi
gram
stain
cerebrospin
fluid
csf
neg
half
case
usual
diagnosi
made
cultur
organ
csf
blood
patient
listeria
bacteremia
undergo
lumbar
punctur
even
absenc
cn
sign
mortal
rate
much
higher
cn
diseas
present
infect
respond
well
antibiot
therapi
relaps
may
occur
routin
use
tmpsmx
effect
prevent
may
explain
listeriosi
observ
less
frequent
current
era
aspergillosi
import
caus
cn
infect
immunocompromis
patient
common
portal
entri
lung
invas
sinu
infect
also
occur
less
common
patient
aspergillosi
typic
risk
factor
renal
dysfunct
requir
augment
immunosuppress
type
transplant
also
import
lung
liver
transplant
recipi
suscept
transplant
patient
aspergillu
angiotrop
mold
hematogen
spread
brain
occur
earli
cours
infect
cn
imag
reveal
singl
multipl
enhanc
lesion
predilect
graywhit
junction
galactomannan
detect
blood
csf
patient
fungi
may
caus
parenchym
brain
infect
transplant
recipi
includ
mucoral
dematiac
fungi
toxoplasma
gondii
absenc
prevent
therapi
cmv
infect
evid
cultur
viru
viral
protein
nucleic
acid
occur
symptomat
diseas
organ
transplant
recipi
primari
infect
occur
seroneg
recipi
seroposit
donor
like
symptomat
proport
infect
patient
becom
symptomat
also
function
intens
immunosuppress
absolut
viral
load
chang
viral
load
import
determin
symptomat
infect
ie
cmv
diseas
see
chapter
common
type
cmv
diseas
mononucleosi
syndrom
character
fever
focal
symptom
abnorm
may
found
liver
function
test
although
jaundic
rare
occur
tissueinvas
diseas
may
manifest
pneumon
gastrointestin
diseas
hepat
era
prolong
antivir
prophylaxi
routin
use
cmv
diseas
organ
transplant
recipi
often
late
manifest
approxim
case
tissueinvas
diseas
interstiti
pneu
monia
seriou
complic
cmv
infect
present
fatal
case
fever
dyspnea
hypoxemia
diffus
infiltr
chest
radiograph
typic
find
bronchoalveolar
lavag
bal
lung
biopsi
requir
diagnosi
cmv
pneumonia
may
coexist
pathogen
lung
particularli
pneumocysti
one
troublesom
manifest
cmv
diseas
ulcer
gastrointestin
tract
ulcer
often
multipl
may
found
anywher
esophagu
rectum
sever
complic
bleed
perfor
occur
patient
cmv
diseas
consid
differenti
diagnosi
transplant
recipi
fever
acut
subacut
abdomin
symptom
especi
transplant
occur
within
past
month
recent
intensif
immunosuppress
definit
diagnosi
depend
endoscopi
cmv
may
involv
inaccess
part
bowel
cmv
hepat
occur
liver
transplant
recipi
common
primari
reactiv
infect
patholog
find
microabscess
scatter
around
liver
lobul
cmv
inclus
bodi
may
easi
find
scant
diseas
typic
mild
may
incident
find
asymptomat
patient
undergo
liver
biopsi
evalu
elev
liver
enzym
intraven
ganciclovir
prefer
agent
treatment
sever
symptomat
cmv
diseas
transplant
recipi
howev
oral
valganciclovir
reason
altern
care
select
nonsever
ill
patient
therebi
simplifi
therapi
patient
cmv
diseas
viremia
therapi
typic
continu
resolut
cmv
viremia
risk
relaps
lower
patient
detect
cmv
dna
ganciclovir
therapi
although
ganciclovir
prove
effect
administr
requir
parenter
access
larg
random
multicent
trial
victor
studi
demonstr
oral
valganciclovir
safe
longterm
outcom
noninferior
intraven
ganciclovir
treatment
cmv
diseas
nonsever
ill
organ
transplant
patient
foscarnet
cidofovir
also
activ
cmv
use
infrequ
solidorgan
recipi
side
effect
gener
use
patient
ganciclovirresist
cmv
ganciclovirresist
cmv
emerg
import
complic
transplant
associ
donor
seroposit
recipi
seroneg
statu
potent
immunosuppress
prolong
incomplet
suppress
antivir
drug
exposur
diagnosi
suspect
transplant
recipi
without
clinic
virolog
respons
fulldos
ganciclovir
therapi
confirm
genotyp
resist
test
directli
clinic
specimen
eg
blood
bal
mutat
specif
region
confer
resist
ganciclovir
wherea
mutat
region
confer
resist
ganciclovir
cidofovir
foscarnet
either
alon
variou
combin
algorithm
manag
suspect
ganciclovirresist
cmv
transplant
recipi
publish
greatest
advanc
regard
cmv
infect
transplant
recent
year
develop
accur
reproduc
quantit
method
includ
intern
laboratori
standard
routin
use
antivir
prophylaxi
preemptiv
therapi
howev
current
recommend
hsv
reactiv
transplant
approxim
recipi
absenc
antivir
prophylaxi
half
person
develop
symptomat
oral
genit
lesion
genit
herp
may
becom
clinic
evid
first
time
transplant
distress
patient
reactiv
hsv
usual
occur
first
week
transplant
viscer
infect
caus
hsv
report
case
hsv
hepat
liver
transplant
hsv
pneumonia
lung
transplant
rare
event
primari
hsv
infect
occur
earli
transplant
donor
organ
may
sourc
primari
hsv
infect
may
produc
sever
septic
syndrom
hypotens
dissemin
intravascular
coagul
case
reactiv
hsv
infect
easili
diagnos
respond
well
antivir
therapi
use
antivir
prophylaxi
seroposit
patient
prevent
hsv
infect
reason
approach
prefer
patient
risk
viscer
hsv
infect
lung
liver
transplant
recipi
lowdos
acyclovir
mg
twice
daili
first
week
transplant
usual
suffici
herp
zoster
report
patient
figur
depict
cumul
incid
herp
zoster
cohort
transplant
recipi
organ
type
induct
therapi
tcell
antibodi
predictor
develop
herp
zoster
antivir
therapi
indic
heal
often
slow
transplant
recipi
occasion
develop
neurolog
complic
dissemin
infect
oral
therapi
acyclovir
valacyclovir
famciclovir
suffic
dermatom
zoster
patient
ophthalm
zoster
evid
dissemin
intraven
acyclovir
use
initi
primari
vzv
infect
chickenpox
transplant
patient
also
usual
requir
admiss
hospit
treatment
intraven
acyclovir
although
pediatr
heart
transplant
recipi
low
dose
immunosuppress
success
treat
oral
valacyclovir
obtain
serolog
result
vzv
transplant
identifi
patient
risk
primari
infect
vaccin
counsel
avoid
report
exposur
varicellaseroneg
transplant
recipi
expos
may
benefit
use
varicellazost
immun
globulin
given
day
exposur
howev
administ
soon
possibl
pcr
howev
limit
low
specif
nephropathi
specif
pcr
diagnosi
enhanc
quantit
bk
viru
blood
higher
viral
load
greater
specif
nephropathi
although
noninvas
assay
play
import
role
biopsi
remain
use
definit
diagnosi
stage
diseas
implic
prognosi
identifi
concomit
process
reject
etc
natur
histori
studi
kidney
transplant
recipi
shown
predict
pattern
progress
bk
viru
infect
initi
detect
bk
viru
urin
blood
progress
bk
viru
nephropathi
typic
cours
month
advent
quantit
pcr
assay
primari
approach
prevent
progress
bk
viru
nephropathi
use
preemptiv
reduct
immunosuppress
guid
viral
load
assay
typic
blood
histolog
evid
diseas
develop
reduct
immunosuppress
may
improv
stabil
renal
function
nearli
one
third
one
half
patient
still
progress
kidney
failur
antivir
agent
cidofovir
leflunomid
fluoroquinolon
ivig
report
use
therapi
anecdot
report
definit
evid
agent
effect
lack
progress
multifoc
leukoencephalopathi
pml
occur
patient
impair
tcell
immun
caus
jc
viru
unlik
situat
acquir
immunodefici
syndrom
pml
occur
patient
low
count
pml
rare
transplant
patient
develop
profound
neurolog
deficit
includ
variou
motor
sensori
visual
cognit
find
occur
subacut
cours
week
month
brain
biopsi
requir
definit
diagnosi
diagnosi
strongli
suggest
find
characterist
white
matter
chang
magnet
reson
imag
mri
jc
viru
dna
pcr
csf
proven
therapi
pml
report
document
stabil
improv
reduct
withdraw
immunosuppress
feasibl
overal
prognosi
dismal
mortal
vast
major
patient
within
month
diagnosi
recent
describ
polyomavirus
includ
ki
wu
merkel
cellassoci
polyomaviru
incid
risk
factor
clinic
associ
outcom
remain
fulli
elucid
unlik
herp
virus
human
herpesviru
infect
ubiquit
geograph
restrict
highest
seropreval
found
central
southern
africa
middl
east
european
countri
border
mediterranean
assess
viral
load
implement
effect
prophylact
preemptiv
regimen
prevent
diseas
caus
cmv
topic
discuss
chapter
respiratori
viral
infect
receiv
littl
mention
earli
report
infect
organ
transplant
recogn
import
pathogen
recent
avail
pcr
techniqu
detect
virus
play
import
role
help
diagnos
infect
adenovirus
common
problem
pediatr
adult
transplant
may
caus
asymptomat
infect
also
caus
diffus
pneumonia
necrot
hepat
hemorrhag
cystiti
antivir
agent
ribavirin
cidofovir
use
treat
adenoviru
infect
effect
remain
uncertain
respiratori
virus
includ
rsv
parainfluenza
metapneumoviru
coronaviru
rhinoviru
import
caus
upper
lower
tract
infect
organ
transplant
recipi
avail
highli
sensit
molecular
diagnost
test
significantli
improv
abil
make
definit
diagnosi
suggest
transplant
patient
may
prolong
shed
virus
season
vari
accord
specif
viru
therapeut
option
limit
ribavirin
appear
activ
vitro
rsv
howev
conclus
proof
efficaci
lack
aerosol
prepar
use
treat
rsv
lung
infect
stem
cell
lung
transplant
popul
overal
impact
respiratori
virus
appear
significantli
greater
lung
compar
organ
transplant
recipi
influenza
document
frequent
transplant
patient
recent
studi
particularli
among
lung
transplant
recipi
influenza
associ
substanti
morbid
mortal
organ
transplant
patient
earli
therapi
associ
better
clinic
outcom
immunocompromis
person
includ
transplant
recipi
appear
increas
risk
develop
resist
neuraminidas
inhibitor
transplant
patient
household
contact
given
yearli
immun
inactiv
influenza
vaccin
although
immun
respons
appear
diminish
compar
nonimmunosuppress
person
consider
also
given
provid
antivir
prophylaxi
highrisk
patient
outbreak
influenza
polyomaviru
infect
urinari
tract
first
describ
renal
transplant
recipi
almost
year
ago
subsequ
studi
shown
polyomavirus
detect
renal
transplant
patient
decad
discoveri
virus
occasion
associ
transient
renal
dysfunct
ureter
stenosi
sinc
late
polyomavirus
bk
viru
specif
emerg
import
caus
nephropathi
renal
transplant
recipi
frequent
lead
graft
failur
almost
case
respons
polyomaviru
bk
viru
jc
viru
detect
patient
pathogen
role
less
well
establish
known
bk
nephropathi
emerg
recent
usual
explan
introduct
new
potent
immunosuppress
medic
howev
nonren
transplant
patient
receiv
similar
immunosuppress
rare
develop
bk
viru
nephropathi
indic
factor
immunosuppress
uniqu
renal
allograft
import
bk
viru
infect
develop
either
via
primari
infect
commun
donor
transmit
reactiv
infect
particularli
major
adult
seroposit
allograft
reject
result
treatment
may
import
predispos
factor
patient
polyomaviru
nephropathi
typic
fever
symptom
infect
present
rise
serum
creatinin
bk
viru
primarili
infect
renal
tubular
cell
produc
intranuclear
groundglass
inclus
accompani
interstiti
nephriti
fig
polyomavirus
may
detect
urin
varieti
techniqu
includ
cultur
cytolog
electron
microscopi
occur
marrow
recipi
autolog
ebvspecif
ctl
also
expand
vitro
solidorgan
transplant
recipi
ptld
clinic
experi
use
cell
therapi
limit
signific
technic
advanc
made
ongo
clinic
trial
underway
assess
feasibl
efficaci
adopt
therapi
prevent
treatment
ptld
solidorgan
transplant
recipi
although
patient
infect
mosquitoborn
rna
viru
remain
asymptomat
clinic
diseas
may
manifest
abrupt
onset
headach
malais
gastrointestin
disturb
gener
adenopathi
retroorbit
pain
rare
rash
risk
west
nile
viru
wnv
neuroinvas
diseas
may
high
may
manifest
enceph
mening
poliomyelitislik
ill
acut
flaccid
paralysi
csf
typic
reveal
neutrophil
pleocytosi
occasion
mollaretlik
cell
diagnosi
reli
serolog
pcr
test
serum
csf
detect
csf
wnv
igm
consid
diagnost
neuroinvas
diseas
csf
pcr
less
sensit
csf
igm
antibodi
diagnosi
viremia
often
transient
may
use
diagnosi
acut
infect
support
therapi
remain
mainstay
manag
anecdot
report
describ
efficaci
wnvspecif
immunoglobulin
ivig
high
titer
wnv
antibodi
howev
remain
experiment
mani
center
perform
organ
transplant
care
select
hivinfect
person
suppress
hiv
load
count
cell
mcl
outcom
kidney
transplant
gener
compar
nonhivinfect
recipi
although
liver
transplant
appear
inferior
relat
hcv
hbv
coinfect
experi
organ
transplant
limit
interact
immunosuppress
hiv
drug
complic
manag
might
respons
rel
high
rate
reject
seen
hivposit
kidney
transplant
recipi
acceler
hiv
infect
increas
rate
opportunist
infect
report
major
problem
hivposit
transplant
recipi
recent
renal
transplant
hivposit
donor
recipi
report
high
incid
area
south
africa
addit
legal
barrier
use
hivposit
donor
remov
unit
state
estim
transplant
complic
donorderiv
infect
ddi
rate
expect
increas
larg
result
improv
recognit
report
event
although
infrequ
ddi
associ
substanti
morbid
mortal
death
occur
recipi
document
transmiss
viral
infect
account
nearli
one
third
confirm
ddi
transmiss
certain
virus
eg
cmv
ebv
hcv
hbv
expect
occur
predict
howev
risk
mitig
use
appropri
prophylact
measur
recipi
minim
impact
posttranspl
outcom
unexpect
ddi
eg
lymphocyt
choriomening
viru
rabi
wnv
hiv
document
devast
sequela
infect
occur
diseas
suspect
recogn
donor
time
death
bacteremia
donor
contamin
organ
procur
donor
respiratori
tract
colon
lung
transplant
may
result
transmiss
bacteri
infect
tuberculosi
diseas
untreat
latent
infect
may
transmit
allograft
donorderiv
tuberculosi
often
unrecogn
particularli
area
low
preval
inde
tuberculosi
one
common
bacteri
caus
ddi
unit
state
recipi
allograft
donor
inadequ
treatment
incomplet
unreli
histori
prior
activ
latent
tuberculosi
receiv
chemoprophylaxi
transplant
candidiasi
common
donortransmit
mycosi
case
due
contamin
preserv
fluid
occur
kidney
transplant
recipi
donor
cryptococcosi
includ
infect
strongli
link
kaposi
sarcoma
transplant
case
occur
patient
seroposit
transplant
indic
reactiv
infect
current
estim
seroposit
patient
develop
kaposi
sarcoma
first
year
transplant
although
recent
studi
suggest
risk
clinic
diseas
may
lower
transmiss
transplant
allograft
subsequ
develop
kaposi
sarcoma
also
document
transplant
recipi
kaposi
sarcoma
present
mucocutan
lesion
gastrointestin
lesion
seen
patient
lung
lymph
node
involv
occur
approxim
one
half
transplant
patient
kaposi
sarcoma
experi
regress
tumor
reduct
immunosuppress
switch
calcineurin
inhibitor
sirolimu
associ
tumor
regress
patient
respond
chang
immunosuppress
requir
chemotherapi
mortal
rang
depend
extent
viscer
involv
primari
ebv
infect
occur
three
fourth
seroneg
pediatr
adult
transplant
recipi
reactiv
infect
defin
viremia
pcr
detect
one
third
seroposit
transplant
recipi
infect
occur
within
first
month
transplant
import
diseas
associ
ebv
infect
transplant
recipi
posttransplant
lymphoprolif
disord
ptld
patient
ptld
evid
ebv
infect
serolog
rise
measur
ebv
viral
load
saliva
peripher
blood
risk
ptld
higher
transplant
recipi
ebv
seroneg
transplant
patient
seroposit
major
risk
factor
ptld
use
high
dose
immunosuppress
especi
polyclon
monoclon
antibodi
formul
direct
cell
detect
high
viral
load
ebv
blood
pcr
associ
high
risk
ptld
studi
predict
power
find
need
valid
larger
prospect
studi
ptld
variabl
present
may
resembl
infecti
mononucleosi
without
evid
tissu
involv
except
tonsil
peripher
lymph
node
anoth
manifest
diffus
polymorph
bcell
infiltr
viscer
organ
type
may
preced
mononucleosislik
episod
either
evolv
directli
tissu
infiltr
process
tempor
separ
third
clinic
present
appear
local
extranod
lymphoma
gastrointestin
tract
thorax
part
bodi
includ
brain
mostli
bcell
lymphoma
usual
contain
ebv
genom
detect
nucleic
acid
hybrid
ebvspecif
antigen
detect
immunohistochemistri
tumor
may
either
monoclon
oligoclon
determin
immunoglobulin
g
igg
lightchain
phenotyp
immunoglobulin
gene
rearrang
studi
typic
host
rather
donor
origin
antivir
agent
acyclovir
ganciclovir
inhibit
lytic
phase
ebv
infect
virion
product
replic
cell
latent
infect
ebv
definit
evid
use
antivir
medic
provid
benefit
treat
prevent
ptld
theoret
consider
data
retrospect
studi
suggest
posttransplant
antivir
prophylaxi
may
decreas
overal
incid
ptld
reduct
elimin
immunosuppress
may
lead
regress
ptld
one
half
case
regress
like
tumor
appear
first
year
transplant
polymorph
appear
contain
tumor
cell
polyclon
laboratori
studi
treatment
ptld
infus
monoclon
antibodi
direct
surfac
antigen
b
cell
theoret
attract
approach
achiev
initi
remiss
two
third
patient
ptld
tumor
malign
phenotyp
requir
chemotherapi
infus
human
leukocyt
antigen
hla
compat
ebvspecif
cytotox
lymphocyt
ctl
found
effect
treatment
case
ptld
unrecogn
cryptococc
meningoenceph
may
transmit
yeast
allograft
activ
histoplasmosi
undiagnos
presum
asymptomat
infect
donor
resolv
time
death
result
donorderiv
histoplasmosi
potenti
donor
endem
area
either
activ
occult
infect
also
transmit
coccidioidomycosi
gener
donor
undiagnos
meningoenceph
suitabl
donat
transmiss
fungal
pathogen
diseas
includ
prion
infect
balamuthia
may
occur
tabl
rare
instanc
aspergillosi
filament
fungi
includ
agent
mucormycosi
also
transmit
infect
donor
recent
fungi
emerg
seriou
complic
transplant
tourism
practic
travel
abroad
commerci
acquir
organ
associ
graft
loss
death
case
heart
transplant
donor
recipi
serotest
toxoplasmosi
given
pauciti
cyst
noncardiac
tissu
screen
nonheart
donor
toxoplasmosi
routin
perform
donor
screen
chaga
diseas
perform
live
travel
endem
area
